Sites
Our Strategic Growth Enables Your Success
Jubilant HollisterStier CMO provides comprehensive sterile fill-finish and lyophilization services, ensuring the consistent delivery of high-quality products that meet the needs of global healthcare markets and patients worldwide. Our ongoing expansion projects reflect our dedication to providing our partners with state-of-the-art technology and expanded capacity while maintaining our commitment to white-glove service.
Spokane, Washington
Sterile Fill-Finish & Lyophilization Expertise
Our high-capacity Spokane site focuses on sterile fill-finish and lyophilization for both clinical and commercial-scale projects. With advanced isolator technology, automated inspection systems, and a strong FDA inspection history, Spokane is built to handle complex formulations and high-volume production efficiently. JHS opened its third line in February 2024, marking the completion of the first half of our state-of-the-art expansion project.
Spokane Expansion
Our ongoing facility expansion featuring two high-speed, fully integrated sterile fill-finish lines with isolator technology, additional lyophilizers, and cold storage doubles our total capacity and addresses your needs as a pharma innovator or public health organization operating today. The expansion has already allowed us to create hundreds of new jobs, and we estimate having created about 400 new positions in Spokane by the end of 2026. A portion of the $300 million USD raised for the expansion project came from an active partnership with the US government to support a national response to future public health emergencies.
We are finalizing our fourth high-speed injectable-liquid filling line, which will open in 2026. The 160,000 sq. ft. expansion and the addition of larger lyophilizers will further increase our capacity. The line 4 expansion also includes additional operational space with a build-out, loading docks, ultra-cold storage and temperature-controlled capabilities, a high-speed packaging line, environmental monitoring, stability space, and a new employee services area. Once line 4 is live, JHS will be able to produce approximately 60 million vials and service over 300 million patients a year worldwide.
Montréal, Quebec
Montréal Expansion
We announced an investment of $114 million USD to expand Canadian operations. At completion, the expansion aims to triple its Montréal annual capacity from 20 million to 70 million injectables in addition to its current ophthalmic capabilities. The Canadian government and Health Canada are supporting the project through partially repayable loans and the Strategic Innovation Fund (SIF). Additionally, we are undergoing validation for a 200-bottle-per-minute filling line that can handle both traditional three-piece and preservative-free bottles that is on track to open by early 2026.
Ready to get started?
JHS delivers white-glove service and world-class sterile injectable manufacturing—tailored to your product, your timeline, and your goals.
Connect with our team today and discover how we can bring your drug product to your patients quickly.